Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance
- PMID: 27860186
- PMCID: PMC5502673
- DOI: 10.1111/liv.13312
Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance
Abstract
Background & aims: Drug induced liver injury (DILI) is challenging because of the lack of biomarkers to predict mortality. Our aim was to describe miRNA changes in sera of subjects with acute idiosyncratic DILI and determine if levels of miRNAs were associated with 6 month mortality.
Methods: Clinical data and sera were collected from subjects enrolled in the Drug Induced Liver Injury Network prospective study. miRNAs were isolated from serum obtained from 78 subjects within 2 weeks of acute DILI and followed up for 6 months or longer. miRNAs were compared to 40 normal controls and 6 month survivors vs non-survivors.
Results: The mean age of the DILI cohort was 48 years, and 55% were female. Eleven (14.1%) subjects died, 10 within 6 months of DILI onset, 5 (45%) liver related. Lower levels of miRNAs-122, -4463 and -4270 were associated with death within 6 months (P<.05). None of the subjects with miRNA-122 greater than the median value died within 6 months for a sensitivity of 100% and specificity of 57%. In subjects with a serum albumin <2.8 g/dL and miR-122<7.89 RFU the sensitivity, specificity, positive and negative predictive values for death within 6 months were 100%, 57%, 38% and 100% respectively.
Conclusions: Serum miRNA-122 combined with albumin accurately identified subjects who died within 6 months of drug induced liver injury. If confirmed prospectively, miRNA-122 and albumin may be useful in identifying patients at high risk for mortality or liver transplantation.
Keywords: albumin; drugs; hepatotoxicity; herbals; prognosis.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Conflict of interest statement
Conflicts of Interest: None
Figures




Similar articles
-
Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury.Toxicol Sci. 2015 Feb;143(2):268-76. doi: 10.1093/toxsci/kfu232. Epub 2014 Oct 29. Toxicol Sci. 2015. PMID: 25359176
-
Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.Gastroenterology. 2014 Jul;147(1):96-108.e4. doi: 10.1053/j.gastro.2014.03.045. Epub 2014 Mar 27. Gastroenterology. 2014. PMID: 24681128 Free PMC article.
-
Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury.J Gastroenterol Hepatol. 2013 Jan;28(1):161-7. doi: 10.1111/j.1440-1746.2012.07279.x. J Gastroenterol Hepatol. 2013. PMID: 23020522
-
Hopes and challenges in using miRNAs as translational biomarkers for drug-induced liver injury.Biomark Med. 2013 Apr;7(2):307-15. doi: 10.2217/bmm.13.9. Biomark Med. 2013. PMID: 23547824 Review.
-
Latest advances in diagnosing and predicting DILI: what was new in 2017?Expert Rev Gastroenterol Hepatol. 2018 Oct;12(10):1033-1043. doi: 10.1080/17474124.2018.1512854. Epub 2018 Sep 3. Expert Rev Gastroenterol Hepatol. 2018. PMID: 30111182 Review.
Cited by
-
Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice.Antioxidants (Basel). 2021 Mar 5;10(3):390. doi: 10.3390/antiox10030390. Antioxidants (Basel). 2021. PMID: 33807700 Free PMC article. Review.
-
The MicroRNA-based Liquid Biopsy Improves Early Assessment of Lethal Acetaminophen Poisoning: A Case Report.Am J Case Rep. 2020 Feb 22;21:e919289. doi: 10.12659/AJCR.919289. Am J Case Rep. 2020. PMID: 32086430 Free PMC article.
-
Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review.Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1327-1343. doi: 10.1080/17425255.2021.1999410. Epub 2021 Nov 15. Expert Opin Drug Metab Toxicol. 2021. PMID: 34727797 Free PMC article.
-
Challenges and Future of Drug-Induced Liver Injury Research-Laboratory Tests.Int J Mol Sci. 2022 May 27;23(11):6049. doi: 10.3390/ijms23116049. Int J Mol Sci. 2022. PMID: 35682731 Free PMC article. Review.
-
Blood toxicogenomics reveals potential biomarkers for management of idiosyncratic drug-induced liver injury.Front Genet. 2025 Mar 25;16:1524433. doi: 10.3389/fgene.2025.1524433. eCollection 2025. Front Genet. 2025. PMID: 40201567 Free PMC article.
References
-
- Regev A, Björnsson ES. Drug-induced liver injury: morbidity, mortality and Hy’s Law. Gastroenterology. 2014;147:204. - PubMed
-
- Bonkovsky HL, Jones DP, Russo MW, Shedlofksy SI. Chapter 25–Drug Induced Liver Injury. In: Boyer TD, Manns MP, Sanyal AJ, editors. Zakim and Boyer’s Hepatology A textbook of liver disease. 6th. Elsevier Saunders; Philadelphia: 2012. pp. 417–461.
-
- Zimmerman HY. Hepatotoxicity The adverse effects of drugs and other chemicals in the liver. 2nd. Lippincott Williams & Wilkins; Baltimore: 1999.
Publication types
MeSH terms
Substances
Grants and funding
- U01 DK065211/DK/NIDDK NIH HHS/United States
- U01 DK083027/DK/NIDDK NIH HHS/United States
- U01 DK083020/DK/NIDDK NIH HHS/United States
- U01 DK065201/DK/NIDDK NIH HHS/United States
- U01 DK100928/DK/NIDDK NIH HHS/United States
- U01 DK065238/DK/NIDDK NIH HHS/United States
- U01 DK065193/DK/NIDDK NIH HHS/United States
- U01 DK065176/DK/NIDDK NIH HHS/United States
- U01 DK083023/DK/NIDDK NIH HHS/United States
- UL1 TR001420/TR/NCATS NIH HHS/United States
- U01 DK065184/DK/NIDDK NIH HHS/United States
- U01 DK082992/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical